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In 1994, the molecular basis of pachyonychia congenita (PC) was elucidated. Four keratin genes are associated
with the major subtypes of PC: K6a or K16 defects cause PC-1; and mutations in K6b or K17 cause PC-2. Mutations
in keratins, the epithelial-specific intermediate ﬁlament proteins, result in aberrant cytoskeletal networks which
present clinically as a variety of epithelial fragility phenotypes. To date, mutations in 20 keratin genes are asso-
ciated with human disorders. Here, we review the genetic basis of PC and report 30 new PC mutations. Of these, 25
mutations were found in PC-1 families and ﬁve mutations were identiﬁed in PC-2 kindreds. All mutations identiﬁed
were heterozygous amino acid substitutions or small in-frame deletion mutations with the exception of an unusual
mutation in a sporadic case of PC-1. The latter carried a 117 bp duplication resulting in a 39 amino acid insertion in
the 2B domain of K6a. Also of note was mutation L388P in K17, which is the ﬁrst genetic defect identiﬁed in the
helix termination motif of this protein. Understanding the genetic basis of these disorders allows better counseling
for patients and paves the way for therapy development.
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Keratins Form a Stress-Bearing
Cytoskeleton in Epithelia
Within all eukaryotic cells, there are three cytoskeletal net-
works consisting of microfilaments, microtubules, and in-
termediate filaments, each of which performs specialized
functions (Alberts et al, 1989; Morley and Lane, 1994). Mi-
crofilaments and microtubules are involved in a variety of
functions including cell division, motility, contraction, differ-
entiation, and cell death. Intermediate filament proteins are
encoded by a large family of at least 65 genes that can be
subdivided into six main classes, of which keratins make up
types I and II (Quinlan et al, 1994; Fuchs and Cleveland,
1998; Hesse et al, 2001, 2004). Before the early 1990s, the
function of intermediate filaments was largely unknown.
Then a number of independent studies focusing on keratin
function by a variety of methods including in vitro studies,
transgenic animals, and human molecular genetics con-
cluded that keratins were predominantly structural proteins
giving cells structural resilience to resist physical damage
(McLean and Lane, 1995; Fuchs and Cleveland, 1998; Irvine
and McLean, 1999; Porter and Lane, 2003; Omary et al,
2004). More recent studies support this but also show that
these networks are in fact highly dynamic structures
(Werner et al, 2003; Windoffer et al, 2004). Keratin genes
are clustered to two chromosomal loci; the type I keratins
(K9–K20) on chromosome 17q12–q21 and type II keratins
(K1–K8) are located in a gene cluster on chromosome
12q11q–14. K18 is the exception as it maps to the type II
gene cluster. In terms of nomenclature, the official gene
symbols for keratins are KRT1 for the gene encoding keratin
K1 etc, however, in the keratin literature, these are com-
monly referred to as the K1 gene etc. With analysis of
recent data from the human genome project it is now pre-
dicted that humans possess at least 54 functional keratin
genes (Hesse et al, 2004). In light of the genome data, a
revised gene/protein nomenclature system has been sug-
gested (Hesse et al, 2004) but this has not yet been adopted
by the field. Importantly, keratins are expressed in pairs
consisting of a type I and type II keratin in a tissue- and
differentiation-specific manner (Table I). In other words,
each of the many different epithelial cells and tissues in the
human body express particular combinations of keratins
(Lane, 1993).
All keratins share the same basic protein structure con-
sisting of a central a-helical rod domain of 310 amino acids
flanked by non-helical head (V1) and tail (V2) domains
(Quinlan et al, 1994; Smith et al, 2002), as shown in Fig 1a.
The rod domain is divided into four a-helical domains, the
1A, 1B, 2A, and 2B, which are made up of heptad repeat
units that mediate dimer formation via interaction of recur-
rent hydrophobic residues. The helical segments are con-
nected together by three non-helical linkers, L1, L12, and
L2, which are predicted to provide flexibility to the rod do-
main. Type II keratins have two additional subdomains, H1Abbreviation: PC, pachyonychia congenita
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and H2 located between the rod and tail domains. The H1
subdomain, specific to type II keratins, is essential for po-
lymerization. A ‘‘stutter’’ sequence exists in the centre of the
2B domain, where the helix polarity is reversed. Two short
sequences present at either end of the rod domain, the helix
initiation motif and the helix termination motif, are highly
conserved throughout all intermediate filaments. These he-
lix-boundary motifs are thought to be critical in mediating
end-to-end overlap interactions during filament assembly
(Steinert et al, 1993b).
For each type of keratin, the genomic organization and
position of introns within the coding sequence is the same
(Quinlan et al, 1994). Type I keratins have eight exons and
type II keratins have nine exons. Multiple pseudogenes exist
for many keratins. Many of these are processed, intron-less
pseuodogenes, notably those related to the simple epithe-
lial keratin genes K8 and K18, for which there are nearly 150
pseudogenes in the human genome (Hesse et al, 2001).
Other keratins have conventional intron-containing pseu-
dogenes, in particular the keratins involved in PC, namely
K6, K16, and K17 (Troyanovsky et al, 1992; Takahashi et al,
1995; Smith et al, 1999b). The presence of pseudogenes
whose sequences are highly homologous to the functional
gene, makes genetic analysis difficult using genomic DNA,
as discussed below.
The keratin cytoskeleton forms a network of filaments
extending from the periphery of the nucleus to the plasma
membrane in all epithelial cells (Fig 1b). The assembly of
this network involves several steps and the precise spatial
arrangement of the protein subunits at some stages is still
controversial but should become clearer now that the crys-
tal structure for some parts of certain intermediate filament
proteins are emerging (Herrmann et al, 2000; Strelkov et al,
2001; Herrmann and Foisner, 2003). The first step in keratin
assembly is the formation of obligate heterodimers by par-
allel alignment of a type I and type II keratin. Dimers align to
form tetramers that then polymerize laterally and longitudi-
nally to form 2–3 nm protofilaments. The precise way that
the dimers align is still uncertain; in vitro cross-linking ex-
periments suggest that there could be three possible ways
(Steinert et al, 1993a). During the next stage of assembly
two protofilaments align to form a 4.5 nm protofibril. These
protofibrils inter-twine to form a complete 10 nm keratin
filament consisting of 32 monomer chains in cross section.
Finally, keratin filaments assemble into structurally resilient
cytoskeletal networks.
Table I. Expression patterns of keratins and known keratin disorders
Keratin Tissue expression pattern (s) Disorder
K1, K10 Suprabasal cells of stratified, cornified epithelia Bullous congenital ichthyosiform erythroderma (BCIE)
or epidermolytic hyperkeratosis (EHK); Diffuse non-
epidermolytic palmoplantar keratoderma (DNEPPK)
K2e Late suprabasal cells of stratified cornified epithelia Ichthyosis bullosa of Siemens (IBS)
K2p Specific to hard palate ?
K3, K12 Anterior corneal epithelium Meesmann epithelial corneal dystrophy (MECD)
K4, K13 Mucosa, stratified non-cornified epithelia White sponge nevus (WSN)
K5, K14 Basal keratinocytes of epidermis and stratified
epithelia
Epidermolysis bullosa simplex (EBS)
K6a, K16 Nail bed, palmoplantar epidermis (widespread),
epidermal appendages, oral mucosa, wound healing
Pachyonychia congenita type 1 (PC-1); Focal non-
epidermolytic palmoplantar keratoderma (FNEPPK);
PC-1 tarda
K6b, K17 Nail bed, palmoplantar epidermis (restricted),
epidermal appendages, sebaceous gland, hair shaft,
other epithelia, wound healing
Pachyonychia congenita type 2 (PC-2);
Steatocystoma multiplex (SM); PC-2 tarda
K7 Mesothelium, ductal epithelia, simple epithelia ?
K8a, K18a Simple epithelia; hepatocytes Cryptogenic cirrhosis; Inflammatory bowel disease
K9 Palmoplantar epidermis Epidermolytic palmoplantar keratoderma (EPPK)
K15 Basal keratinocytes ?
K19 Simple epithelia, epidermal appendages ?
K20 Gastrointestinal tract epithelia; Merkel cells ?
hHb6, hHb1, hHb3 Cortical trichocytes of the hair shaft Monilethrix
K6hfa Companion layer of hair follicle Pseudofolliculitis barbae
K6irs Inner root sheath of hair follicle ?
aMutations in these proteins predispose individuals to disease – not purely causative.
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Pachyonychia congenita (PC) is caused by mutations in
one of four keratin genes The discovery of PC as a keratin
disorder was an extension of earlier studies on epidermo-
lysis bullosa simplex (EBS), the first human keratin disorder
to be identified (discussed in McLean et al, this issue). Many
other keratin disorders have been identified resulting, to
date, in 20 human keratin genes associated with single
gene disorders or predisposing factors in complex traits
(Table I). The majority of dominant keratin mutations are
clustered to the helix boundary motifs of these proteins.
PC is a group of inherited disorders of the epidermis and
its appendages which can be divided into two main clinical
subtypes, PC-1 (OMIM 167200) and PC-2 (OMIM 167210;
Munro, 2001), with other rare variants, including PC-tarda
(Paller et al, 1991). The clinical details of these disorders are
described in detail by Leachman et al (this issue). The first
clue that PC was a keratin disorder came from genetic
linkage analysis. A study of a large Scottish pedigree pre-
senting with a typical PC-2 phenotype showed co-segre-
gation of the disease with polymorphic markers within the
type I keratin gene cluster at 17q12–q21, resulting in sta-
tistically significant genetic linkage (Munro et al, 1994). Mu-
tation analysis in this PC-2 family revealed a heterozygous
missense mutation in the K17 gene, which was detected in
all affected members and was absent from all unaffected
family members and 50 unrelated controls (McLean et al,
1995). Simultaneously, a missense mutation was detected
in a sporadic case of PC-1, this time in the K16 gene
(McLean et al, 1995). Another group identified mutations in
the K6a gene in PC-1 families (Bowden et al, 1995; Lin et al,
1999). Later, a mutation was detected in the K6b gene in an
extended family with the PC-2 phenotype, which revealed
that this keratin is the expression partner of K17 (Smith et al,
1998). Thus, it was established that mutations in K6a
or in K16 cause PC-1, whereas mutations in K6b or K17
cause PC-2. Subsequently, further genetic testing has re-
sulted in the identification of mutations in these keratin
genes involving 450 PC families worldwide (http://www.
interfil.org).
Methods for diagnosis and problems in PC molecular
analysis By clinical examination, it is usually possible to
determine the type of PC. Subsequently, molecular analysis
can be performed to identify the exact gene defect (Smith,
2003). This involves DNA sequencing of the two appropriate
candidate keratin genes; K6a and K16 for PC-1 and K6b
and K17 for PC-2. Analysis is normally performed on gen-
omic DNA extracted from blood samples as this is less in-
vasive than obtaining biopsy material. In large families with
several affected members it may be useful to perform link-
age analysis before DNA sequencing (Smith et al, 2004).
Using polymorphic genetic markers within the two keratin
clusters on chromosome 12q (type II) and 17q (type I) it is
often possible to exclude one locus and therefore halve the
amount of DNA sequencing. Even in small families where
statistically significant linkage cannot be obtained it may be
possible to exclude one keratin locus (Smith et al, 2004).
Linkage analysis can also be useful in families where there
are several affected members but clinical distinction be-
tween PC-1 and PC-2 is unclear. Mutation screening nor-
mally focuses first on the two mutation ‘‘hot spots,’’ the
highly conserved helix-boundary motifs at either end of the
rod domain, and then if no mutation is found, analysis can
be extended to other regions.
When performing mutation analysis for PC using gen-
omic DNA, one needs to be aware of the pseudogenes that
are present for all four keratin genes involved. There are at
least two pseudogenes for each of K16 and K17 and a
number of copies of the K6 gene, some of which are ex-
pressed. The early PC mutation studies were carried out on
mRNA derived from skin biopsies to overcome the problem
of pseudogenes (McLean et al, 1995). The sequences of
these pseudogenes, however, are now known making it
possible to design PCR primers to specifically amplify only
the functional genes and avoid amplification of the pseu-
dogenes. Mutation detection strategies based on PCR am-
plification of genomic DNA have been developed for all four
keratin genes involved in PC and primers have been de-
signed to specifically amplify full length K6a, K6b, K16, and
K17 (see Methods). Direct sequencing of the purified PCR
products is carried out using internal primers. Several mu-
tations identified using these methods have also been con-
firmed at the mRNA level confirming specificity of the PCR
primers and the conditions. In the UK, genetic diagnosis is
carried out by National Health Service laboratories (all ker-
atin disorders are analyzed by the Molecular Genetics Lab-
oratory, Human Genetics Unit, Ninewells Hospital, Dundee,
UK) and in the USA by local genetics laboratories or by
private companies such as GeneDx (Gaithersburg, Mary-
land). Genetic testing of patients enrolled in the International
PC Research Registry (IPCRR) is performed by the Dundee
Figure 1
Protein structure of keratins and immunofluorescent staining of
PLK2 cells. (a) Schematic diagram showing the basic protein structure
of a keratin filament. The a-helical rod domain is divided into four do-
mains, the 1A, 1B, 2A and 2B connected together by linkers L1, L12,
and L2. Flanking the rod domain are the highly conserved helix initiation
motif and the helix termination motif, shown in red. Type II keratins have
H1 and H2 subdomains. The ‘‘stutter’’ sequence is marked by S. (b)
Antibody staining of keratin filaments (green) in PtK2 epithelial cells in
culture, nuclei (blue) stained with 40,6-diamidino-2-phenylindole (DAPI).
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laboratory and the results are independently checked by
GeneDx. Useful contacts for PC diagnosis and genetic
testing are listed in Table II.
Many laboratories performing mutation analysis of ker-
atin disorders have a small percentage of patients where no
mutation in the candidate keratin gene(s) is found. This is
also true for PC and based on our experience, about 10% or
so of PC patients fall into this category (Smith and McLean,
unpublished observations). One explanation is that it can be
difficult to fully exclude a gene; the mutation may be in a
region not normally screened. For example, there may be
cryptic splicing elements within large introns, mutations af-
fecting the promoter, or there could be genomic rearrange-
ments because of meiotic mismatch within clusters of highly
homologous isogenes/pseudogenes, as is the case in the
globin gene clusters (Cooper and Krawczak, 1993). Another
possibility is misdiagnosis—in some cases, patients can
present with very similar clinical symptoms but at the mo-
lecular level have mutations in different genes. One example
is PC and Clouston syndrome (OMIM 129500) where there
is some overlap in clinical symptoms. Recently several pa-
tients presenting with variants of PC were screened in our
laboratory for mutations in the candidate genes, K6a, K6b,
K16, and K17. But, no mutations were found and after clin-
ical re-examination, alternative diagnoses were considered.
Screening of the GJB6 gene encoding the gap junction
protein connexin 30 led to identification of mutations and
reclassification of these patients as Clouston syndrome (van
Steensel et al, 2003). In some cases, PC patients have
blisters at birth that resemble EBS and may be initially di-
agnosed with EBS until more characteristic symptoms of
PC develop (Smith et al, 2001).
Results
Clinical details of PC-1 families The PC families analyzed
here were obtained from IPCRR. This is a research registry
resource approved by an Institutional Review Board (IRB)
that complies with all principles of the Helsinki Accord
(Western IRB #1057496). Participant recruitment is primarily
by self-referral to the web-based registry, although a
few families were direct physician referrals to S.A.L. or
W.H.I.M.
Seventeen of the cases showed a strong family history of
PC, consistent with autosomal dominant inheritance (Table
III). As an example, the pedigree of Family 5 is shown in Fig
2a, which demonstrates typical autosomal dominant inher-
itance with male-to-male transmission as seen in both ma-
jor forms of PC. There are affected individuals in at least five
generations, each of whom presented with hypertrophic nail
dystrophy (including hyperkeratosis of the nail bed, with
thickening and deformation of the nail plate, see Fig 2b) and
in a number of cases, oral leukokeratosis. It is notable that
an affected member of this family died at 2 y of age because
of respiratory infection. Although details of this case are not
available, potentially fatal laryngeal involvement in child-
hood PC-1 has been reported on several occasions (Stieg-
litz and Centerwall, 1983; Wudy et al, 1995). The other 13
PC cases analyzed here were sporadic.
The clinical phenotypes of the other PC-1 and PC-2
families studied here were largely unremarkable and entirely
typical of the classic phenotypic spectrum described in
Leachman et al (this issue). In two kindreds (Families 21 and
23), the nail dystrophy phenotype was very limited. Specif-
ically, the fingernails showed no thickening or hyperkerato-
sis whatsoever, although on close examination some
splinter hemorrhages were evident (Fig 2c). There was
hypertrophic dystrophy affecting the distal portions of the
great toenails and some but not all of the minor toenails (not
shown). Focal keratoderma was moderate-severe and quite
typical of that seen in other PC-1 families (not shown). The
clinical appearance was consistent in the affected members
of Family 21 and the sporadic proband in Family 23. Overall,
the phenotype was very similar to that seen in previously
reported FNEPPK families carrying K16 mutations (Shams-
her et al, 1995).
A range of keratin mutations in PC families Here we re-
port keratin mutations in 30 new cases of PC from Canada,
France, Ireland, the Netherlands, Sweden, Finland, UK, and
USA. In PC-1 patients, eight novel mutations were found in
K6a (I167N, L170F, N171S, S176P, I462N, L468P, L469P,
E470ins39) and a further three new mutations in K16 (L124P,
L124H, N125D). In addition, nine recurrent mutations were
detected in K6a (N171del  6, N171K, F174S  2) and a
further five previously reported defects in K16 (N125S  2,
R127C, L132P  2). In PC-2 patients, we identified one
novel mutation (L388P) and two previously reported muta-
tions (N92S  2) in K17, as well as two substitutions in K6b
(E472K  2). All novel mutations were excluded from 50
Table II. Useful websites for research and diagnosis of
pachyonychia congenita
Website URL
On-line Mendelian Inheritance
in Man (OMIM): Clinical and
molecular data on all genetic
disorders
http://www3.ncbi.nlm.nih.gov/
Omim/
Intermediate filament mutation
database: Clinical and
mutational data on keratin
disorders and other
intermediate filament diseases
http://www.interfil.org/
GeneDx: US-based company
offering genetic testing for
keratin disorders, genetic skin
diseases and other disorders.
IPCRR testing lab
http://www.genedx.com/
Human Genetics Unit, Dundee:
UK center for molecular
diagnosis of keratin disorders.
IPCRR testing lab
http://www.humangenetics.
org.uk/
The Pachyonychia Congenita
Project: Charitable organization
offering support for PC patients
and sponsoring PC research
http://www.pc-project.org
TransDerm: US-based
company set up in partnership
with the Pachyonychia
Congenita Project to develop
therapeutics for pachyonychia
congenita
http://www.transderm.org
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normal controls either by DNA sequencing or restriction
enzyme digestion (data not shown). The DNA sequence
traces of the novel mutations are shown in Figs 3–6. The
details of all the mutations identified here and their asso-
ciated clinical phenotypes are summarized in Table III.
Genetic linkage analysis was performed on Family 5 us-
ing microsatellite markers near the type II (D12S1651) and
type I keratin clusters (D17S800 and KRT12). This analysis
conclusively excluded involvement of type I keratins but
was consistent with a type II keratin defect (not shown).
Direct sequencing of K6a genomic DNA PCR products de-
rived from the affected individuals revealed a mutation in
exon 7 of K6a, I462N (Fig 4). For each of the other families
DNA samples were only available from one or two affected
members and so genetic linkage analysis was not possible
and direct gene sequencing was performed.
Table III. Mutations identiﬁed in new PC cases
Family
PC
subtype Occurrence Keratin
Novel/
Recurrent
Protein
change Domain
DNA
change
Screening
method Notes
1. PC-1 Familial K6a Novel I167N 1A, HIM 500T4A Sau3A I site lost
2. PC-1 Familial K6a Novel L170F 1A, HIM 508C4T Sequencing
SOBCs
3. PC-1 Sporadic K6a Novel N171S 1A, HIM 512A4G Blp I site in primer
4. PC-1 Familial K6a Novel S176P 1A, HIM 526T4C Sequencing
5. PC-1 Familial K6a Novel I462N 2B, HTM 1385T4A Sau3A I site lost K16 excluded
by linkage
6. PC-1 Familial K6a Novel L468P 2B, HTM 1403T4C Sequencing
7. PC-1 Sporadic K6a Novel L469P 2B, HTM 1406T4C Sequencing
8. PC-1 Sporadic K6a Novel E470ins39 2B, HTM 1410ins117 Sequencing
9. PC-1 Sporadic K16 Novel L124P 1A, HIM 371T4C Xcm I site gained
10. PC-1 Sporadic K16 Novel L124H 1A, HIM 371T4A Sequencing
11. PC-1 Familial K16 Novel N125D 1A, HIM 373A4G Sequencing
12. PC-1 Sporadic K6a Recurrent N171del 1A, HIM 511-513del N/A
13. PC-1 Sporadic K6a Recurrent N171del 1A, HIM 511-513del N/A
14. PC-1 Familial K6a Recurrent N171del 1A, HIM 511-513del N/A
15. PC-1 Familial K6a Recurrent N171del 1A, HIM 511-513del N/A
16. PC-1 Sporadic K6a Recurrent N171del 1A, HIM 511-513del N/A
17. PC-1 Familial K6a Recurrent N171del 1A, HIM 511-513del N/A
18. PC-1 Familial K6a Recurrent N171K 1A, HIM 513C4A N/A
19. PC-1 Sporadic K6a Recurrent F174S 1A, HIM 521T4C N/A
20. PC-1 Sporadic K6a Recurrent F174S 1A, HIM 521T4C N/A
21. FNEPPK Familial K16 Recurrent N125S 1A, HIM 374A4G N/A Minor nail
changes and
PPK
22. PC-1 Familial K16 Recurrent N125S 1A, HIM 374A4G N/A
23. FNEPPK Sporadic K16 Recurrent R127C 1A, HIM 379C4T N/A No nail changes,
no oral lesions,
PPK
24. PC-1 Familial K16 Recurrent L132P 1A, HIM 395T4C N/A
25. PC-1 Familial K16 Recurrent L132P 1A, HIM 395T4C N/A
26. PC-2 Familial K17 Novel L388P 1A, HIM 1163T4C MspI digest natal teeth
noted
27. PC-2 Sporadic K17 Recurrent N92S 1A, HIM 275A4G N/A
28. PC-2 Sporadic K17 Recurrent N92S 1A, HIM 275A4G N/A
29. PC-2 Familial K6b Recurrent E472K 1A, HIM 1459G4A N/A
30. PC-2 Familial K6b Recurrent E472K 1A, HIM 1459G4A N/A
HIM, helix initiation motif; HTM, helix termination motif.
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Most mutations were missense or small in-frame deletion
mutations in the known keratin hotspot regions, as sum-
marized in Table III. A small number of mutations, however,
were unusual. In Family 8, the proband, who was a sporadic
case, had a very unusual mutation: a 117 bp duplication,
1410ins117, in exon 7 of the K6a gene (Fig 4). This resulted in
a 39 amino acid insertion in the 2B domain of the K6a po-
lypeptide (E470ins39), which duplicates the latter part of the
2B domain including a portion of the helix termination motif.
The mutation was confirmed by cloning the PCR product (Fig
4). Despite the unusual nature of this genetic lesion, the PC-1
phenotype of this patient was unremarkable.
In Family 26, the affected persons carried a missense
mutation in K17, L388P which is the first reported mutation in
the helix termination motif of this protein (Fig 6). In this case,
the phenotype was well within the normal spectrum associ-
ated with PC-2 (see Leachman et al, this issue). Specifically,
affected persons in this kindred had typical nail dystrophy,
pilosebaceous cysts, plantar keratoderma and more than
one affected member of the family had natal teeth.
Interestingly, the two kindreds who presented with a
milder, site-restricted PC-1 phenotype of FNEPPK with mild
nail changes (Families 21 and 23), carried the same muta-
tions as previously reported in similar unrelated FNEPPK
families, N125S and R127C, respectively, in K16 (Shamsher
et al, 1995). The milder nail changes consisted mainly of
splinter hemorrhages of the fingernails and mild nail plate
thickening affecting only one or two toenails. The fingernails
of an affected member of Family 21 are shown in Fig 2. In
contrast, the affected persons in Family 22 were also found
to carry the N125S mutation in K16, but here, the presen-
tation was more typical of PC-1, with 17 out of 20 nails in
the proband showing typical hypertrophic nail dystrophy
(not shown). Thus, we see here a good example of inter-
familial phenotypic variation. Similarly, the affected mem-
bers of Family 11, who carried a different mutation in the
same residue of K16, N125D, had a more typical PC-1
Figure2
Pedigree of family 5 and clinical
features of families 5 and 4. (a)
Part of the pedigree of Family 5
showing typical autosomal domi-
nant inheritance of PC-1. Asterisks
denote individuals from whom DNA
was obtained. (b) Striking hypertro-
phic dystrophy of the fingernails in
a patient from Family 5, carrying a
heterozygous missense mutation
I462N in K6a. (c) The fingernails of
the proband in Family 21 showing
complete lack of thickening and
only minor splinter hemorrhages.
This patient carries a heterozygous
missense mutation N125S in K16.
Figure 3
Keratin 6A, exon 1 mutation analysis. (a) Normal K6a sequence in
exon 1, showing codons 166-170. (b) The equivalent sequence shown in
(a) from the proband in Family 1, missense mutation 500T4A (arrow)
results in the amino acid substitution I167N. (c) Normal K6a sequence in
exon 1, codons 174–178. (d) The equivalent sequence shown in (c) from
the proband in Family 4 showing missense mutation 526T4C (arrow)
resulting in amino acid substitution S176P. (e) Normal K6a sequence in
exon 1, from codons 169–173. (f) Analogous region of K6a shown in (e)
from the proband in Family 2 showing missense mutation 508C4T (ar-
row) resulting in amino acid change L170F. (g) The equivalent sequence
shown in (e) from the proband in Family 3 showing missense mutation
512A 4G (arrow) resulting in amino acid change N171S.
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presentation with severe hypertrophic nail dystrophy affect-
ing both hands and feet.
Also of special interest are the mutations in Families 29
and 30, both of which are familial cases of PC-2. Here, the
mutations were found in K6b, the type II expression partner
of K17. Both families carry the same K6b mutation reported
previously in a Dutch family, E472K (Smith et al, 1998). Ha-
plotype analysis showed that Family 29 was unrelated to the
previously reported family and so this is an independent
occurrence of the same mutation. Haplotype analysis was
not possible in Family 30 because of lack of samples, but as
these kindreds originate from different parts of North Amer-
ica and neither has known Dutch ancestry, it is likely that
these represent independent occurrences of the E472K
mutation. Consistent with this hypothesis is the fact that the
equivalent mutation in K2e is a recognized CpG hotspot
mutation which has been found to occur in many different
unrelated ichthyosis bullosa of Siemens families and spo-
radic cases (Basarab et al, 1999).
Discussion
Here we have reviewed the genetic basis of PC and the
current methods for mutation analysis. Using these meth-
ods, we report 30 new mutations: 12 novel and 18 recurrent.
These new mutations support the fact that the type of PC
can be identified consistently at the molecular level. Spe-
cifically, mutations in K6a or K16 produce the PC-1 or
closely related FNEPPK phenotypes, whereas mutations in
K6b or K17 result in a phenotype with more widespread
Figure 4
Keratin 6A, exon 7 mutation analysis. (a) Normal K6a sequence in
exon 7, showing codons 461–465. (b) The equivalent sequence shown
in (a) from an affected individual in Family 5 showing missense mutation
1385T 4A (arrow) leading to amino acid change I462N. (c) Normal K6a
sequence in exon 7, codons 467–473. (d) The equivalent sequence
shown in (c) from the proband in Family 6 showing missense mutation
1403T 4C (arrow) resulting in amino acid change L468P. (e) Analogous
region of K6a shown in (c) from the proband in Family 7 showing mis-
sense mutation 1406T 4C (arrow) resulting in amino acid change
L469P. (f) Normal K6a sequence in exon 7, from codons 467–473. (g)
The equivalent sequence shown in (f) from the proband in Family 8
showing unusual insertion mutation 1410ins117 (overlapping se-
quence, arrow) leading to insertion of 39 amino acids (E470ins39). (h)
The equivalent sequence shown in (f) from a clone derived from PCR
product from the proband in Family 8 to confirm mutation 1410ins117
(E470ins39, arrow).
Figure5
Keratin 16 mutation analysis. (a) Normal K16 sequence in exon 1,
showing codons 122–126. (b) Analogous region of K16 from the pro-
band in Family 9 showing missense mutation 371T4C (arrow) leading
to amino acid substitution L124P. (c) The equivalent sequence shown in
(a) from the proband in Family 10 showing missense mutation 371T4A
(arrow) resulting in amino acid change L124H. (d) K16 exon 1 sequence
derived from the proband in Family 11, missense mutation 373A4G
(arrow) results in the amino acid change N125D.
Figure6
Keratin 17 mutation analysis. (a) Normal sequence of K17 exon 6
showing codons 386–390. (b) The equivalent sequence shown in (a)
from the proband in Family 26 showing missense mutation 1163T4C
(arrow) resulting in amino acid change L388P.
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pilosebaceous cysts either with hypertrophic nail dystrophy
(PC-2) or without it (steatocystoma multiplex). There is so
far only one notable exception to this rule, in a case where
there was considerable clinical overlap between PC-1 and
PC-2 (Ward et al, 2003). This patient reportedly had multiple
soft, yellow papules and nodules that were confirmed his-
tologically as steatocysts and here, a mutation was found at
the ‘‘hot spot’’ codon of K6a (N171). As pilosebaceous cysts
do not normally appear until puberty in PC-2 and steatocy-
stoma multiplex patients, there is an obvious role for an-
drogens in their pathogenesis. It is therefore possible that
inter-individual variation in androgen levels may modulate
the formation of pilosebaceous cysts in PC. It should also
be noted that PC-1 patients do appear to get more cysts
arising from the pilosebaceous unit than was previously
noted, however, these are usually fewer in number and are
more site-restricted than the cysts seen in PC-2 (see
Leachman et al, this issue).
All the novel PC-1 mutations reported here were in the
helix boundary motifs of either K6a or K16, consistent with
previous findings (Table III). The N171 codon of K6a is
emerging as a mutation hotspot in PC-1. Here, we found
one novel mutation N171S and seven recurrent ones
(N171K and N171del  6) further highlighting this codon.
Including these mutations, 16 out of 52 reported PC-1 mu-
tations (30.8%) occur within this codon (this paper and mu-
tation database, http://www.interfil.org). Presently this is the
most common codon for mutation in PC-1 although there
are several other codons both in K6a and K16 where re-
current mutations have been found in unrelated families
(K6a F174; K16 L132). Interestingly, in Families 21 and 23,
who presented with FNEPPK and milder nail dystrophy
confined to a few toenails, we found the same K16 muta-
tions N125S and R127C as previously reported in FNEPPK
families (Shamsher et al, 1995). In Family 22 studied here,
however, the same N125S mutation resulted in more typical
PC-1, with most nails being affected. Similarly, Family 11
had a different amino acid substitution at the same codon
(N125D) and again had the more severe nail phenotype
typical of PC-1. Although it is tempting to speculate that
N125S in K16 is more often associated with more restricted
FNEPPK-like phenotypes, when one compares the pheno-
types in affected members of Families 21 and 22, all of
whom carry this specific defect, interfamilial phenotypic
variation is clearly at play. Thus, it is important not to make
firm conclusions about phenotypes associated with partic-
ular genotypes until large numbers of cases are available.
In PC-2 the majority of the mutations are in the helix
initiation motif of K17 with mutations at two codons, N92
and R94 accounting for more than 50% of cases (http://
www.interfil.org). The two PC-2 cases reported here were
again at codon N92. Similar to K16, mutations at the same
codon can produce different phenotypes: N92S and N92D
cause PC-2 and in one case N92H resulted in steatocysto-
ma multiplex. More surprising is that the same K17 muta-
tion, R94C, can lead to PC-2 or the milder steatocystoma
multiplex phenotype with no nail changes (Smith et al, 1997;
Covello et al, 1998; Wang et al, 2001). Therefore genotype–
phenotype correlation in keratin disorders has a level of
complexity that is not fully understood at the present time. It
is likely that in addition to the mutation, a combination of
other factors, both genetic and environmental, are involved
in determining the overall clinical phenotype. As more fam-
ilies are analyzed it may be possible to draw better geno-
type–phenotype correlations in the future (as discussed by
McLean et al, this issue).
In the small number of PC-2 families studied here, we
identified two further instances of the E472K mutation in
K6b, confirming that mutations in this gene phenocopy
mutations in K17 (Smith et al, 1998). This confirms the co-
expression of K6b and K17 as a keratin pair in humans at
least, as previously shown (Smith et al, 1998). The first oc-
currence of a mutation affecting the K17 helix termination
motif was also identified here, producing a fairly typical PC-
2 presentation in Family 26, including some cases of natal
teeth, a hallmark of PC-2. All previous K17 mutations
(n¼26) have been located in the 1A domain (see Leachman
et al, this issue and McLean et al, this issue).
Conclusions
In conclusion, PC is caused by mutations in four differen-
tiation-specific keratin genes. Methods are now available to
rapidly diagnose PC at the molecular level despite the dif-
ficulties arising from these being multiple copy genes.
Knowledge of the exact gene defect allows for better ge-
netic counseling and in cases of severe PC, if requested,
the option of prenatal diagnosis. When the familial mutation
is known, this can be performed at an early stage of preg-
nancy by chorionic villus biopsy, as we have previously
demonstrated (Smith et al, 1999b). In addition, knowing the
molecular basis of PC will undoubtedly help in the rational
design of novel gene-based or drug-based therapies for
these conditions, which remain incurable at this time.
Methods
Genetic linkage analysis Genomic DNA was extracted from pe-
ripheral blood lymphocytes by a standard procedure, with in-
formed consent and appropriate ethical approval in all cases.
Genetic linkage analysis was performed on Family 5 using fluo-
rescently labeled polymorphic markers, as described previously
(van Steensel et al, 1999).
Mutation detection and conﬁrmation: general considera-
tions The full length K6a, K6b, K16, and K17 genes were ampli-
fied by long-range PCR, using primers specific to the respective
functional genes to avoid amplification of additional K6 genes or
K16/K17 pseudogenes, as previously described (Smith et al, 1998,
1999a, b; Terrinoni et al, 2001). As it can be difficult to perform
long-range PCR using low quality DNA samples, we have also
developed two shorter PCR reactions covering all exons of the K6a
gene, described below. PCR reactions were optimized on a Hybaid
0.5 mL Multiblock PCR machine but may need to be re-calibrated
for other thermocyclers. The primer pairs and conditions currently
in use in our laboratory are given below.
K6aP1-P2 fragment (5.5 kb, encompassing all exons) For-
ward primer K6AP1 (50 CCA GCC TCT CAC ACT CTC CTC 30) and
reverse primer K6AP2 (50 GAC CGA GAG CTA GCA GAC GC 30)
were used in High Fidelity PCR buffer (Roche, Lewes, East Sussex,
UK) containing 1.5 mM MgCl2 and 4% dimethylsulphoxide (DMSO).
A ‘‘hot start’’ was performed with 1U High Fidelity thermostable
DNA polymerase mix (Roche) and the following conditions were
28 SMITH ET AL JID SYMPOSIUM PROCEEDINGS
used: (941C for 5 min)  1; (941C 30 sec, 611C 1.5 min, 721C 2.5
min)  35; and (721C 5 min)  1.
K6aSP1L2-R2 fragment (3.8 kb fragment, from promoter to in-
tron 6) Forward primer K6aSP1L2 (50 CCG GGC TTA TTG TGT
TAG GA 30) and reverse primer K6aSP1R2 (50 TCC AGG GAA GCC
AAA ATA CT 30) were used in High Fidelity PCR buffer (Roche)
containing 1.0 mM MgCl2. A ‘‘hot start’’ was performed with 1 U
High Fidelity thermostable DNA polymerase mix (Roche) and the
following conditions were used: (941C for 5 min)  1; (941C 30
sec, 551C 1.5 min, 721C 2.5 min)  35; and (721C 5 min)  1.
K6aSP2L2-R2 fragment (2.0 kb fragment, from intron 6 to
downstream of exon 9) Forward primer K6aSP2L2 (50 ACT CCA
AAC AAA CCA GCA GG 30) and reverse primer K6aSPR2 (50 TAA
CTT GCT CTA GTT GGC CG 30) were used in High Fidelity PCR
buffer (Roche) containing 1.0 mM MgCl2. A ‘‘hot start’’ was per-
formed with 1 U High Fidelity thermostable DNA polymerase mix
(Roche) and the following conditions were used: (941C for 5 min)
 1; (941C 30 sec, 551C 1.5 min, 721C 2.5 min)  35; and (721C
5 min)  1.
K16SP2-SP3 fragment (2.5 kb fragment covering all ex-
ons) Primers, K16SP2 (50 AGG GCT CCT GCG GCA TCG GA 30
forward) and K16SP3 (50 GGA TTG GCC AGA TGC TTG CT 30
reverse) were used in High Fidelity PCR buffer (Roche) containing
1.5 mM MgCl2 and 4% DMSO. A ‘‘hot start’’ was performed with
1 U Taq polymerase (Promega, Southampton, UK). The following
PCR conditions were used: (941C 5 min)  1; (941C 30 sec, 591C
45 sec, 721C 2 min)  35; and (721C 5 min)  1.
K6bP1-P2 fragment (5.5 kb fragment covering all exons) For-
ward primer K6bP1 (50 CTC CAG CCT CTC ACA CTC TCC TA 3)
and reverse primer K6bP2 (50 CTT CTC AGA ATT ATG GCA GAC
TCA G 30) were used in High Fidelity PCR buffer (Roche) containing
1.5 mM MgCl2 and 4% DMSO. A ‘‘hot start’’ was performed with
1 U High Fidelity thermostable DNA polymerase mix (Roche). Re-
actions were amplified using the following extended PCR program:
(941C 5 min  1); (941C 20 sec, 561C 1 min 30 sec, 681C 3 min)
 10; (941C 20 sec, 561C 1 min 30 sec, 681C 3 min plus 20 sec
increment/cycle)  20; and (681C 10 min)  1.
K17P8-P10 fragment (1 kb covering exon 1) Primers K17P8 (50
GCC TAT AAA GGA AGC GGG C 30) and reverse primer K17P10 (50
CTC CTT TCT GCC TCC TCC 30) were used with Qiagen PCR
buffer containing 1.0 mM MgCl2 and 1U HotStar Taq DNA polym-
erase (Qiagen, Crawley, UK). Reactions were amplified using the
following program: (941C for 15 min)  1; (941C 1 min, 581C
1 min, 721C 1 min)  30; and (721C 5 min)  1.
K17e6L-E6R (400 bp fragment covering exon 6) Primers
K17e6L (50 CAG AAG AGG GCA TTG ACC AT 30) and reverse
primer K17e6R (50 CCC CAG GGC CGA AGC CAC GC 30) were
used in Qiagen PCR buffer containing 1.0 mM MgCl2 and 1U Hot-
Star Taq DNA polymerase (Qiagen). Reactions were amplified us-
ing the following program: (941C for 15 min)  1; (941C 1 min,
581C 1 min, 721C 1 min)  35; and (721C 5 min)  1.
PCR products were purified for sequencing using QIA quick
PCR purification kit (Qiagen) and sequenced using internal primers.
Sequencing ladders were analyzed on an ABI 377 or 3100 auto-
mated DNA sequencers, according to manufacturer’s instructions.
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